August 2, 2025Open Access

Immune cell senescence drives responsiveness to immunotherapy in melanoma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Case control study identifies immune cell senescence influencing treatment responses in melanoma, suggesting potential therapeutic strategies.

Immune cell senescence affects responsiveness to immunotherapy in melanoma patients.
Non-responders showed higher senescence in CD8+ T-cells, CD4+ T-cells, B-cells, and NK cells.
A novel senescence signature, SeneVick, was validated using single cell RNA-seq analysis.
Findings indicate that targeting immune cell senescence may improve immunotherapy outcomes.

Pantelis et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Case control study identifies immune cell senescence influencing treatment responses in melanoma, suggesting potential therapeutic strategies.